Clonal myeloid disorders following CAR T-cell therapy

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
² Division of Hematology/Oncology, University of Massachusetts Memorial Medical Center, Worcester, MA, USA.
³ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
⁴ Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA.
⁵ Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA. rpatell@bidmc.harvard.edu.

Michael Andersen Jr et al. Ann Hematol. 2023 Dec.

. 2023 Dec;102(12):3643-3645.

doi: 10.1007/s00277-023-05454-5. Epub 2023 Sep 26.

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
² Division of Hematology/Oncology, University of Massachusetts Memorial Medical Center, Worcester, MA, USA.
³ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
⁴ Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA.
⁵ Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA. rpatell@bidmc.harvard.edu.

No abstract available

References

1. Larson RC, Maus MV (2021) Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 21(3):145–161 - DOI - PubMed - PMC
1. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365 - DOI - PubMed
1. Jain T, Olson TS, Locke FL (2023) How I treat cytopenias after CAR T-cell therapy. In: Blood. Elsevier
1. Alkhateeb HB, Mohty R, Greipp P et al (2022) Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Cancer J. 12(7):1–5 - DOI
1. Cordeiro A, Bezerra ED, Hirayama AV et al (2020) Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant 26(1):26–33 - DOI - PubMed